Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Payables (2019 - 2025)

Historic Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $2.9 million.

  • Fulcrum Therapeutics' Payables fell 2932.44% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 2932.44%. This contributed to the annual value of $1.2 million for FY2024, which is 5778.02% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Payables of $2.9 million as of Q3 2025, which was down 2932.44% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Payables registered a high of $6.0 million during Q1 2022, and its lowest value of $1.2 million during Q4 2024.
  • Moreover, its 5-year median value for Payables was $3.7 million (2021), whereas its average is $3.6 million.
  • In the last 5 years, Fulcrum Therapeutics' Payables skyrocketed by 3101.17% in 2023 and then crashed by 6092.82% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Payables (Quarter) stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then plummeted by 57.78% to $1.2 million in 2024, then surged by 145.36% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $1.8 million for Q2 2025, and $1.5 million during Q1 2025.